T. Rowe Price Investment Management
CYTK icon

T. Rowe Price Investment Management’s Cytokinetics CYTK Stock Holding History

T. Rowe Price Investment Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.59B Buy
18,718,498
+1,194,658
+7% +$85.8M 1.05% 18
2026
Q1 		$1.15B Sell
17,523,840
-192,532
-1% -$12.2M 0.8% 25
2025
Q4 		$1.13B Sell
17,716,372
-1,364,124
-7% -$84.9M 0.71% 31
2025
Q3 		$1.05B Buy
19,080,496
+1,478,056
+8% +$60.9M 0.64% 32
2025
Q2 		$582M Buy
17,602,440
+7,647,189
+77% +$266M 0.37% 75
2025
Q1 		$400M Sell
9,955,251
-796,872
-7% -$36.6M 0.26% 109
2024
Q4 		$506M Buy
10,752,123
+1,062,136
+11% +$55.2M 0.31% 92
2024
Q3 		$512M Buy
9,689,987
+1,551,310
+19% +$86.5M 0.31% 88
2024
Q2 		$441M Buy
8,138,677
+3,017,088
+59% +$182M 0.28% 94
2024
Q1 		$359M Buy
5,121,589
+2,892,104
+130% +$224M 0.22% 117
2023
Q4 		$186M Buy
2,229,485
+413,299
+23% +$15M 0.12% 195
2023
Q3 		$53.5M Buy
1,816,186
+11,870
+0.7% +$395K 0.04% 354
2023
Q2 		$58.9M Buy
1,804,316
+286,254
+19% +$10.6M 0.04% 353
2023
Q1 		$53.4M Buy
1,518,062
+1,054,416
+227% +$43M 0.04% 357
2022
Q4 		$21.2M Buy
+463,646
New +$19.9M 0.02% 451

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

T. Rowe Price Investment Management's CYTK Position: Q2 2026 in Review

T. Rowe Price Investment Management increased its Cytokinetics (CYTK) stake by 6.8% in Q2 2026, buying an estimated $85.8M and bringing the position to 18,718,498 shares worth $1.59B. The position accounts for 1.05% of the portfolio, ranked #18.

T. Rowe Price Investment Management first reported a position in CYTK in Q4 2022 and has held it in 15 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • T. Rowe Price Investment Management held 18,718,498 shares of Cytokinetics worth $1.59B as of Q2 2026.
  • T. Rowe Price Investment Management bought 1,194,658 Cytokinetics shares in Q2 2026, an estimated $85.8M.
  • Cytokinetics made up 1.05% of T. Rowe Price Investment Management's portfolio in Q2 2026, its #18 holding.
  • T. Rowe Price Investment Management first reported a position in Cytokinetics in Q4 2022 and has held it in 15 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.